Loading...
Loading...
Analysts at Cowen & Company downgraded Ironwood Pharmaceuticals
IRWD from Outperform to Market Perform.
The target price for Ironwood Pharmaceuticals has been lowered from $16 to $10.50.
Ironwood shares have gained 4.25% over the past 52 weeks, while the S&P 500 index has jumped 20.88% in the same period.
Ironwood Pharmaceuticals' shares fell 0.92% to close at $12.99 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in